MDCO 216

Drug Profile

MDCO 216

Alternative Names: AIM; ApoA1 Milano; ESP-24217; ET-216; ETC-216; MDCO-216; r-ApoA-I Milano; rApoA-IM; rApoA-IM protein (dimer)

Latest Information Update: 30 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Esperion Therapeutics; The Medicines Company
  • Class Ischaemic heart disorder therapies; Phosphatidylcholines; Phospholipids
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis

Most Recent Events

  • 07 Nov 2016 Discontinued - Phase-I for Coronary artery disease in USA due to lack of effficacy (IV)
  • 07 Nov 2016 Discontinued - Phase-II for Acute coronary syndromes in Canada, Czech Republic, Netherlands, Poland, Hungary and USA due to lack of effficacy (IV)
  • 26 Oct 2016 The Medicines Company initiates the phase II MILANO DRIVE trial for Acute coronary syndromes in Hungary (IV, Infusion) (EudraCT2014-005462-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top